Browse CDKN2C

Summary
SymbolCDKN2C
Namecyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
Aliases INK4C; p18-INK4C; CDK6 inhibitor p18; cyclin-dependent inhibitor; cyclin-dependent kinase 6 inhibitor p18; p ......
Chromosomal Location1p32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain -
Function

Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB.

> Gene Ontology
 
Biological Process GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0000082 G1/S transition of mitotic cell cycle
GO:0001558 regulation of cell growth
GO:0001933 negative regulation of protein phosphorylation
GO:0006469 negative regulation of protein kinase activity
GO:0007050 cell cycle arrest
GO:0010001 glial cell differentiation
GO:0016049 cell growth
GO:0030308 negative regulation of cell growth
GO:0033673 negative regulation of kinase activity
GO:0042063 gliogenesis
GO:0042326 negative regulation of phosphorylation
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045786 negative regulation of cell cycle
GO:0045926 negative regulation of growth
GO:0048709 oligodendrocyte differentiation
GO:0051348 negative regulation of transferase activity
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:1904029 regulation of cyclin-dependent protein kinase activity
Molecular Function GO:0004857 enzyme inhibitor activity
GO:0004860 protein kinase inhibitor activity
GO:0004861 cyclin-dependent protein serine/threonine kinase inhibitor activity
GO:0016538 cyclin-dependent protein serine/threonine kinase regulator activity
GO:0019207 kinase regulator activity
GO:0019210 kinase inhibitor activity
GO:0019887 protein kinase regulator activity
GO:0030291 protein serine/threonine kinase inhibitor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04110 Cell cycle
Reactome R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-69231: Cyclin D associated events in G1
R-HSA-69236: G1 Phase
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-2559585: Oncogene Induced Senescence
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
Summary
SymbolCDKN2C
Namecyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
Aliases INK4C; p18-INK4C; CDK6 inhibitor p18; cyclin-dependent inhibitor; cyclin-dependent kinase 6 inhibitor p18; p ......
Chromosomal Location1p32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CDKN2C and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCDKN2C
Namecyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
Aliases INK4C; p18-INK4C; CDK6 inhibitor p18; cyclin-dependent inhibitor; cyclin-dependent kinase 6 inhibitor p18; p ......
Chromosomal Location1p32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CDKN2C in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 1.08; FDR: 0.009650 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCDKN2C
Namecyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
Aliases INK4C; p18-INK4C; CDK6 inhibitor p18; cyclin-dependent inhibitor; cyclin-dependent kinase 6 inhibitor p18; p ......
Chromosomal Location1p32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CDKN2C in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3760.311
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.5410.8
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2430.861
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4280.227
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.9530.419
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2290.883
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2990.439
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1940.882
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4330.767
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0750.959
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2330.919
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2620.0484
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CDKN2C in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCDKN2C
Namecyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
Aliases INK4C; p18-INK4C; CDK6 inhibitor p18; cyclin-dependent inhibitor; cyclin-dependent kinase 6 inhibitor p18; p ......
Chromosomal Location1p32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDKN2C. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCDKN2C
Namecyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
Aliases INK4C; p18-INK4C; CDK6 inhibitor p18; cyclin-dependent inhibitor; cyclin-dependent kinase 6 inhibitor p18; p ......
Chromosomal Location1p32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDKN2C. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDKN2C.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCDKN2C
Namecyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
Aliases INK4C; p18-INK4C; CDK6 inhibitor p18; cyclin-dependent inhibitor; cyclin-dependent kinase 6 inhibitor p18; p ......
Chromosomal Location1p32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDKN2C. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCDKN2C
Namecyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
Aliases INK4C; p18-INK4C; CDK6 inhibitor p18; cyclin-dependent inhibitor; cyclin-dependent kinase 6 inhibitor p18; p ......
Chromosomal Location1p32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CDKN2C expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCDKN2C
Namecyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
Aliases INK4C; p18-INK4C; CDK6 inhibitor p18; cyclin-dependent inhibitor; cyclin-dependent kinase 6 inhibitor p18; p ......
Chromosomal Location1p32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CDKN2C and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCDKN2C
Namecyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4)
Aliases INK4C; p18-INK4C; CDK6 inhibitor p18; cyclin-dependent inhibitor; cyclin-dependent kinase 6 inhibitor p18; p ......
Chromosomal Location1p32.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CDKN2C collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.